

Liang-Zhong Xu,<sup>a\*</sup> Kai Li,<sup>a</sup>  
 Jin-Hong Liu,<sup>b</sup> Kai Zhou,<sup>a</sup>  
 Wei-Hua Li<sup>c</sup> and Bao-Rong Hou<sup>d</sup>

<sup>a</sup>College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, People's Republic of China, <sup>b</sup>Luoyang Caijing Xuexiao, Luoyang 471002, Henan, People's Republic of China, <sup>c</sup>College of Chemistry and Chemical Engineering, Ocean University of China, Qingdao 266033, People's Republic of China, and <sup>d</sup>Institute of Oceanology, Chinese Academy of Sciences, Qingdao, 266071, People's Republic of China

Correspondence e-mail:  
 liangzhong\_xu@yahoo.com.cn

**Key indicators**

Single-crystal X-ray study  
 T = 294 K  
 Mean  $\sigma(C-C)$  = 0.003 Å  
 R factor = 0.041  
 wR factor = 0.102  
 Data-to-parameter ratio = 15.1

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


1-(4-Fluorophenyl)-2-[4-phenyl-5-[(1H-1,2,4-triazol-1-yl)methyl]-4H-1,2,4-triazol-3-ylsulfanyl]ethanone

The crystal structure of the title compound, C<sub>19</sub>H<sub>15</sub>FN<sub>6</sub>OS, is stabilized by a weak intermolecular C—H···N hydrogen-bond interaction.

Received 6 June 2005  
 Accepted 27 June 2005  
 Online 6 July 2005

**Comment**

The triazole motif appears frequently in the structures of various natural products and biologically active compounds. Some 1,4-disubstituted thiosemicarbazide, 1,2,4-triazoline-3-thione and 1,2,4-triazole-3-thiole derivatives are of interest because of their bioactivities, including antibacterial (Goswami *et al.*, 1984), antifungal (Eid *et al.*, 1994) and anti-tubercular (Kalyoncuoglu *et al.*, 1992) properties.



In the title molecule, (I), atoms S1, N4, N5, N6, C4 and C5 are coplanar (plane *p*<sub>1</sub>). Atom C3 lies in the plane of the triazole ring (N1/N2/N3/C1/C2; plane *p*<sub>2</sub>). The dihedral angles formed by the C6—C11 phenyl ring, the C14—C19 benzene ring and *p*<sub>2</sub> with *p*<sub>1</sub> are 85.22 (9), 38.03 (7) and 86.82 (8)°, respectively. There is a weak C—H···N intermolecular hydrogen-bond interaction stabilizing the crystal structure (Table 2).

**Experimental**

A mixture of 5-[(1H-1,2,4-triazol-1-yl)methyl]-4-phenyl-2H-1,2,4-triazole-3(4H)-thione (0.01 mol), 2-chloro-1-(4-fluorophenyl)-ethanone (0.01 mol) and potassium carbonate (0.01 mol) was stirred in acetone (30 ml) for 4 h at 327 K to afford the title compound (3.03 g, yield 76.8%). Single crystals suitable for X-ray measurements were obtained by recrystallization from ethanol at room temperature.

*Crystal data*

C<sub>19</sub>H<sub>15</sub>FN<sub>6</sub>OS  
 M<sub>r</sub> = 394.43  
 Monoclinic, *P*2<sub>1</sub>/*c*  
 a = 11.838 (3) Å  
 b = 14.976 (3) Å  
 c = 10.611 (3) Å  
 β = 95.996 (4)°  
 V = 1870.9 (8) Å<sup>3</sup>  
 Z = 4

D<sub>x</sub> = 1.400 Mg m<sup>-3</sup>  
 Mo Kα radiation  
 Cell parameters from 2159 reflections  
 θ = 2.8–22.4°  
 μ = 0.21 mm<sup>-1</sup>  
 T = 294 (2) K  
 Block, colourless  
 0.24 × 0.20 × 0.18 mm

## Data collection

Bruker SMART CCD area-detector diffractometer	3823 independent reflections
$\varphi$ and $\omega$ scans	2178 reflections with $I > 2\sigma(I)$
Absorption correction: multi-scan (SADABS; Sheldrick, 1996)	$R_{\text{int}} = 0.042$
$T_{\text{min}} = 0.951$ , $T_{\text{max}} = 0.964$	$\theta_{\text{max}} = 26.4^\circ$
10428 measured reflections	$h = -14 \rightarrow 14$
	$k = -18 \rightarrow 13$
	$l = -11 \rightarrow 13$

## Refinement

Refinement on $F^2$	$w = 1/[\sigma^2(F_o^2) + (0.0323P)^2 + 0.5833P]$
$R[F^2 > 2\sigma(F^2)] = 0.042$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.102$	$(\Delta/\sigma)_{\text{max}} = 0.001$
$S = 1.00$	$\Delta\rho_{\text{max}} = 0.17 \text{ e } \text{\AA}^{-3}$
3823 reflections	$\Delta\rho_{\text{min}} = -0.20 \text{ e } \text{\AA}^{-3}$
253 parameters	
H-atom parameters constrained	

Table 1

Selected geometric parameters ( $\text{\AA}$ ,  $^\circ$ ).

S1—C5	1.742 (2)	N3—C3	1.452 (3)
S1—C12	1.806 (2)	N4—C6	1.436 (3)
C5—S1—C12	97.37 (11)	N4—C5—S1	121.22 (16)
N3—C3—C4	111.99 (17)	C7—C6—N4	119.1 (2)

Table 2

Hydrogen-bond geometry ( $\text{\AA}$ ,  $^\circ$ ).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
C12—H12B $\cdots$ N1 <sup>i</sup>	0.97	2.44	3.400 (3)	171

Symmetry code: (i)  $x, -y + \frac{3}{2}, z + \frac{1}{2}$ .

All H atoms were placed in calculated positions, with C—H = 0.93–0.97  $\text{\AA}$ , and included in the final cycles of refinement using a riding model, with  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ .




Figure 1

View of the title compound, with displacement ellipsoids drawn at the 40% probability level.

Data collection: *SMART* (Bruker, 1998); cell refinement: *SAINTE* (Bruker, 1999); data reduction: *SAINTE*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Bruker, 1999); software used to prepare material for publication: *SHELXTL*.

## References

- Bruker (1998). *SMART*. Bruker AXS Inc., Madison, Wisconsin, USA.  
 Bruker (1999). *SAINTE* and *SHELXTL*. Bruker AXS Inc., Madison, Wisconsin, USA.  
 Eid, A. I., Ragab, F. A., El-Ansary, S. L., El-Gazayerly, S. M. & Mourad, F. E. (1994). *Arch. Pharm.* **327**, 211–213.  
 Goswami, B. N., Katakly, J. C. S. & Baruah, J. N. (1984). *J. Heterocycl. Chem.* **21**, 1225–1229.  
 Kalyoncuoğlu, N., Rollas, S., Sür-Altiner, D., Yeğenoğlu, Y. & Anđ, Ö. (1992). *Pharmazie*, **47**, 796–797.  
 Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany.  
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.